Nomura Instinet analyst Christopher Marai raised his price target for Sarepta Therapeutics to $230 following the company’s Q4 results and keeps a Buy rating on the shares. Positive MYO-101 data in LGMD2E “substantially de-risked” the company’s muscle-focused gene therapy platform, Marai tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.